- Joined
- 29 December 2008
- Posts
- 247
- Reactions
- 0
I see AUD $527 Million on Sinochem's balance sheet, and they have not quite twice that much as debt already on their balance sheet.
So how are these guys going to pull off a $3B merger proposal?
Assume that Sinochem earns roughly AUD $150M per year (that was my rough calculation for 2008 based on the Renminbi denominated financials showing on Reuters). Assume that Nufarm can add in another $150M per year. Assume they finance the AUD $3B buyout as a 10 year loan at 9% interest. That means they have AUD $450M in interest payments each year, and they cannot afford to do this deal?
Guys, can we pool together on this and maybe someone else can show me the errors in the calculation? It doesn't look to me like Sinochem can afford to do this deal.
I see AUD $527 Million on Sinochem's balance sheet, and they have not quite twice that much as debt already on their balance sheet.
So how are these guys going to pull off a $3B merger proposal?
Assume that Sinochem earns roughly AUD $150M per year (that was my rough calculation for 2008 based on the Renminbi denominated financials showing on Reuters). Assume that Nufarm can add in another $150M per year. Assume they finance the AUD $3B buyout as a 10 year loan at 9% interest. That means they have AUD $450M in interest payments each year, and they cannot afford to do this deal?
Guys, can we pool together on this and maybe someone else can show me the errors in the calculation? It doesn't look to me like Sinochem can afford to do this deal.
NUF has an unusual balance date, 31 July, due to the particular seasonal nature of its business. It also has a very unbalanced seasonal business, typically showing a build up in inventory and borrowings in the first half and often showing a loss for this period.
I havn't seen accounts for the last three quarters and wasn't aware that NUF issued quarterly accounts but the balance sheet as at 31 July 08 showed total debt of $939m. As at 31 January 2009 it was $1655m, reflecting the above seasonal trend.
I am still pretty confused about how to reconcile their cash flow to their balance sheet or income statement. According to Reuter's data, for the last three six month reporting periods:
Period ending Jan 31, 2008: $552.3M net debt repaid/retired
Period ending Jul 31, 2008: $452M net debt repaid/retired
Period ending Jan 31, 2009: $539M net debt repaid/retired
Does that agree with your source?
Hi p.
I think you're mis-reading the data.
It looks to me like net issuance of stock/debt of $505.5m, $580.6m and $491.9m respectively for the three sixmonthly periods - from the Reuters site.
I read it backwards you are right. So they took down that much debt, and increased cash accordingly. But the balance sheet doesn't show increasing cash balances. Income statement also doesn't show losses. So where did they spend all of that cash?
My guess is that it will show up in the buildup of inventories, particularly at the two January half year dates. That's the nature of this particular business.
There it is; you are right. I see the inventory build, but I never see the inventory letting up. Given the macroeconomic situation, I wonder if we don't see a big write down of inventory at some point.
P.S., I'm an official Nufarm owner as of yesterday. While I calculate that Sinochem cannot afford much more than a $11 offer on typical financing terms, I have to remember that Sinochem is an ex government enterprise, so probably they can pull in some strings to get some extraordinary financing arrangement. Enough analysts published a $14 target bid that there must be merit to that number.
An article on Bloomberg says "Sinochem could offer between A$12 and A$15 a share for Nufarm, according to David Halliday, a trader at Macquarie Group Ltd." Frankly that's not a lot of upside to the investment, and if the negotiations collapse we are back to $9 quickly.
So $2 down and up to $5 up is not a great trade, but my secret hope is that the early press release gets us a competitive bid. With competition from a larger firm, I think we could get a $17 to $19 bid. At the same EBITDA multiple as the prior Chinese bid, we would be looking at a $21 bid. That's obviously not very likely to repeat, as it's just a different era now much less accepting of highly geared deals.
I got the exposure through NFNG. Upside is a bit over 20% at current price. I am hoping there is support around 75AUD mark if the deal didn't go through, and should still get dividend as long as the business is profitable.
What is NFNG, and what is relationship to Nufarm? Does Nufarm have some kind of income security? What is the symbol for NFNG?
NFNG is the convertible note for Nufarm. (NFNG is the code). It has a face value of 100AUD and currently trading at 83AUD. From the prospectus Nufarm will redeem the note at face value if the company is being taken over. It is paying an interest of 6 months BBSW + 1.9% margin, due to step up in 2011. I got it a few weeks back after the profit warning, thought it is a less risky way of getting exposure to any takeover activity.
NFNG is the convertible note for Nufarm. (NFNG is the code). It has a face value of 100AUD and currently trading at 83AUD. From the prospectus Nufarm will redeem the note at face value if the company is being taken over. It is paying an interest of 6 months BBSW + 1.9% margin, due to step up in 2011. I got it a few weeks back after the profit warning, thought it is a less risky way of getting exposure to any takeover activity.
NFNG is the convertible note for Nufarm. (NFNG is the code). It has a face value of 100AUD and currently trading at 83AUD. From the prospectus Nufarm will redeem the note at face value if the company is being taken over. It is paying an interest of 6 months BBSW + 1.9% margin, due to step up in 2011. I got it a few weeks back after the profit warning, thought it is a less risky way of getting exposure to any takeover activity.
I tried to edit my last message in place and the system timed me out. Dang.
I am confused by the reset in 2011. The 2008 annual report says that on 11/24/2011 they can EITHER "reset" OR "step up" the security.
Let's take step up. That would mean they must pay 1.9% + 7.48%? Since the instrument is described on some sites as "floating rate" it is not clear to me whether 7.48% is a hard number that would be stepped up.
Does the security have a perpetual step up feature, 1.9% every five years?
I'm more concerned by the "reset" option. What does that mean? Does that mean they get to look at rates on similar instruments and reset the base rate? They do state "reset" as an "OR" to "step up" so that implies it is an alternative to step up.
If they are paying a fixed rate 7.48%, at current prices they have an effective annual yield just under 10%. Is it right? They claim this is an unfranked dividend rather than interest payment? Why is that? As a non resident I'll have a higher withholding on the unfranked dividend, and it clearly is an interest payment conceptually?
What price did you get in at? It's certainly an interesting way to play this situation. I would like to see price come back to $76.
Where does one get a time graph of BBSW? I saw some indications that it has crashed recently. I guess the recent softening of NFNG's price might simply mirror the fact that BBSW itself is coming down?
They have the option to step up by 1.9%, but the language here is all to Nufarm's favor. If BBSW has crashed, then they "reset" NFNG to a low rate. If inflation takes off and bank paper is getting issued at 12%, then Nufarm simply ignores that and "steps up" to rate 1.9% higher than the prior rate, but still way below the market rate.
I dislike the fact that the board can simply decide to not pay a distribution, and the distribution does NOT accumulate and there is no obligation incurred to pay.
Really this thing looks pretty risky: you have the illiquidity of a bond with none of the protections for principal and no guarantees whatsoever of any coupon payment.
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?